Amyloidosis (continued)
effective therapy
apoprotein A-I, 395
apoprotein A-II, 396
β2-microglobulin, 394
cystatin C, 396
fibrinogen Aα-chain, 395–396
gelsolin, 396
LECT2, 396
lysozyme, 396
reactivity, 394
TTR, 394–395
expert witnesses, 408
extrarenal genitourinary tract, 312
generic diagnosis, 378–379
GI tract (see Gastrointestinal (GI) tract)
heart (see Cardiac amyloidosis)
high-dose therapy and autologous bone marrow
transplantation, 381–382
immunomodulatory derivatives, 382–383
interstitial and peritubular deposits, 307
kidney, 305–306
laser microdissection (LMD), 262
liquid chromatography (see High-performance
liquid chromatography tandem mass
spectrometry-based proteomics)
liver (see Liver)
localized, 379–380
‘loss of chance’ doctrine, 409–411
medicolegal risk, 406
melphalan-based therapies, 382
negligence, 407–408
non-AL/non-AA Amyloidoses, 311–312
patients with different systemic types, 388–389
penis, 315
peripheral nerve (see Peripheral nerve amyloidosis)
physician protections, 411
prostate, 313–314
proteasome inhibitors, 383–384
proteinuria, 306
reevaluation, 389
renal extraglomerular vessels, 307
solid organ transplantation
hereditary amyloidoses, 385–387
nonhereditary systemic amyloidoses, 387–388
standard of care, 408
support groups, 413
suspicm, 377–378
symptoms, 414
systemic, 380
testis, 314, 315
urinary bladder, 313
websites, 413
Amyloidosis diagnosis, 4–5
Amyloidosisonline.com, 413
Amyloidosisupport.com, 413
Amyloidosis support groups (ASG), 414–417
Amyloid stroma, 88
Amyloid types, 261
Anakinra, 400

Anti-β2m antibody, 77
Antisense oligonucleotide (ASO), 395
Antitumor necrosis factor medications, 399–401
Aortic aneurysm, 82, 94
Apolipoprotein A-I (ApoAI), 59–62, 297
Apolipoprotein A-II (ApoAII), 63–64, 297–298
Atherosclerosis, 45, 82, 95
Autoinflammatory diseases, 31–33, 399
Autosomal dominant pyogenic arthritis, 44

B
Beta-2 microglobulin, 69, 253, 269
Biologic medications, 44, 46, 47, 399, 400
Bone marrow biopsy
amyloid deposit detection, 284
flow cytometry, 289
general appearance, 283–284
image analysis, 289
vs. immunofixation electrophoresis and free light
chain analysis, 288–289
marrow aspirate smears, 289
molecular and genetic studies, 289–290
plasma cell dyscrasia
CD138, 284–285
colorimetric in situ hybridization (CISH), 286
kappa and lambda light chain immunoglobulins., 285
pre-and posttreatment, 286–287
specimen analysis, 288
Brevin, 298

C
Calcifying epithelial odontogenic (Pindborg) tumor, 91
Canakinumab, 400
Cardiac amyloid, 86–87
Cardiac amyloidosis
clinical diagnosis, 324–325
clinical features, 324
diagnostic pitfalls, 334
differential diagnosis
giant cell response, 333
hyalin, 334
interstitial and replacement fibrosis, 333
endomyocardial biopsy
amyloid and collagen fibrils, 329, 332
Congo red birefringence, 329–330
fibrils, TEM, 329, 331
histologic patterns, amyloid deposition, 327–328
interstitial nodular pattern, 329
peri-myocytic and arteriolar amyloid deposits,
327–329
semi-thin plastic-embedded myocardium,
329, 331
severe amyloid infiltration, 329–330
immunohistochemical staining, 332–333
localized
isolated atrial amyloidosis (IAA), 319–320
senile aortic amyloid, 320
valvular amyloidosis, 321
Index

morphology
atrial involvement, 325
formalin-fixed heart, 325
valvular and septal involvement, 325–326
venules, adipose tissue, and myocardial interstitium involvement, 326–327
prognosis, 335
systemic
amyloid A protein, 323
apolipoprotein A-I, 323–324
β2-microglobulin, 323
fibrinogen, 324
immunoglobulin light chain, 321
transthyretin, 321, 323
therapy, 335
Carpal tunnel syndrome, 74
Cerebral amyloid angiopathy (CAA), 108–109
Cerebrovascular amyloidosis
amyloid associated neurodegenerative diseases, 106–108
cerebral amyloid angiopathy (CAA), 108–109
neoplasia associated CNS amyloidosis, 109
pituitary amyloid, 109
systemic amyloidosis and CNS involvement, 109
Certolizumab, 400
Cold-induced autoinflammatory syndrome (CIASI).
See NLRP3 gene
Colorimetric in situ hybridization (CISH), 286
Congo red
detection of, amyloid deposits, 130
fibrillary glomerulonephritis, 116
fluorescence, 175
hyalinized collagen, 122
light and heavy chain amyloidosis, 144
liver, 134
localized amyloid, 84
lungs, 135
medullary thyroid carcinoma, 88–89
renal diseases, 115
tissue biopsy specimen, 75, 77
Corneal amyloid, 95–96
Cryoglobulinemic nephropathy
extrarenal, 120–121
hematoxylin and eosin stain, 119–120
pathogenesis, 121
transmission electron microscopy, 119–120
Cryptopyrin associated periodic fever syndromes (CAPS), 41–43
Crystalopathy, renal, 155
Crystalopathy, extrarenal, 159
Cystatin C amyloidosis, 64
clinical diagnosis, 75
destructive spondyloarthopathy, 74
differential diagnosis, 75
epidemiology, 70
pathophysiology, 70–72
prevention, 78
radiological imaging
magnetic resonance imaging (MRI), 76
plain X-rays, 75, 76
scintigraphy, 75
tissue biopsy, 76–77
ultrasound, 75–76
X-ray computed tomography, 76
risk factors, 72–74
scapulohumeral and other arthropathies, 74
specific treatment, 78
supportive treatment, 77–78
visceral involvement, 74–75
Dialysis technique, 78
Differential diagnosis
cryoglobulinemic nephropathy
extrarenal, 120–121
hematoxylin and eosin stain, 119–120
pathogenesis, 121
transmission electron microscopy, 119–120
fibrillary glomerulonephritis
extrarenal, 118
pathogenesis, 118–119
renal, 116–118
hyalinized collagen, 122
hyalinosis, 122
immunotactoid glomerulopathy
extrarenal manifestations, 121–122
pathogenesis, 122
logical approach, 124–125
organized deposits
entities, kidney and extrarenal manifestations, 114–115
history, 113–114
problems, 115–116
other nonspecific fibrils, 122–123
Direct hemoperfusion, 78
E
Electron microscopy
extrarenal, 120–121
noncrystallized immunoglobulin, 161
rhomboid crystal shape, 157–158
Electrophoresis, 275–276
Eprodisate disodium, 400
Etanercept, 399–400
Expert witnesses, amyloidosis, 408
F
Familial amyloidosis, 323
Familial amyloid polyneuropathy (FAP)
apolipoprotein A-I, 370–371
gelsolin, 370
transthyretin, 369–370
Familial cold autoinflammatory syndrome (FCAS), 34, 35, 41–43, 400
Familial Mediterranean fever (FMF), 34–39
Fibrillary glomerulonephritis (nephropathy) extrarenal, 118
pathogenesis, 118–119
renal, 116–118
Fibril proteins, 82, 85, 86, 90–97
Fibrinogen Aα (alpha)-chain amyloidosis, 62, 299
Free light chain (FLC) diagnostic sensitivity, 279–281
quantitation
automated nephelometric assay, 278
Bence Jones proteins, 277
Cystatin C, 279
immunoglobulin G, 278
reference intervals and diagnostic range, 279
Frequent hemodialysis, 73, 78
Gastrointestinal (GI) tract amyloid vs. collagenous colitis, 343, 346
bacterial overgrowth and malabsorption, 340, 343
clinical presentation, 339–340
collagenous colitis, 343, 345
colic and enteric dysmotility, 342, 344
colic tubular adenoma, 343, 346
cross section, tongue, 339–340
dendoscopy mucosa resection, 339, 341
gastric antrum, 340, 342
hematemesis, 340, 342
hyalinized deposits, 339–340
life-threatening hematochezia, 343–344
mesenteric fat, abdominal fat pad, 343, 345
mucosal prolapse type polyps (MPT), 343, 346
muscularis propria, 339, 342
pink amorphous deposit, 339–340
suberosal connective tissue, 343, 345
systemic amyloid
and macroglossia, 339–340
treatment, 343
Gelsolin amyloidosis, 62
Gelsolin protein, 298
Genitourinary amyloid, 312
Glomerulonephritis (GN) with deposits of monoclonal Ig light and heavy chains, 143–144
diagnostic considerations, 150–151
disease spectrum
demographic, clinical, and biological characteristics, 147, 149
pathological findings, 147–149
nonproliferative, 146–147
pathophysiological considerations, 149–150
proliferative
clinical features, 145
clinical follow-up, PGNMID, 146
epidemiology, 144–145
glomerular immunofluorescence staining, 145
immunologic data, 145–146
pathologic findings, 145
transplantation, 146
treatment outcome, 146
therapeutic considerations, 151–152
H
Heart
light/heavy chain deposition disease, 134
restrictive cardiomyopathy, 60–61
senile systemic amyloidosis, 93
visceral involvement, 74
Heavy chain deposition (HCD). See Light and heavy chain deposition disease (LHCDD)
Hemofiltration, 78, 79
Hereditary amyloidosis, 405
apolipoprotein A-I, 59–62
apolipoprotein A-II, 63–64
cystatin C amyloidosis, 64
definition, 53
differential diagnosis, 292
fibrinogen Aα (alpha)-chain, 62
gelsolin, 62
genes involvement
apolipoprotein A-I, 297
apolipoprotein A-II, 297–298
fibrinogen alpha, 299
gelsolin A, 298
LECT2, 300
lysozyme, 299–300
nomenclature, 293, 295
transthyretin, 295–297
genetic testing, 293, 294
LECT, 64–65
lysozyme, 62–63
mass spectrometry, TTR, 293
primary and secondary types, 55
solid organ transplantation
apolipoprotein A-I, 386–387
fibrinogen A alpha-chain, 386
TTR, 386
symptom of, 292
systemic/localized types, 53–55
transthyretin amyloidosis, 57–59
transthyretin plasma protein, 56–57
typical and atypical types, 55
Hereditary autoinflammatory diseases, 33–34
HIDS. See Hyper IgD syndrome (HIDS)
High-performance liquid chromatography tandem mass spectrometry-based proteomics
collision-induced dissociation (CID), 263
germline polymorphisms, 264
peptide complex generation, 263
shotgun vs. targeted proteomics
methodologies, 262
Swissprot, 263
work flow, pictorial representation, 263–264
Hyalinized collagen, 122
Hyalinosis, 122
Hyper IgD syndrome (HIDS), 43–44

I
IL-1 mediated disease, 43
Immunohistochemistry, 130–131
Immunofixation electrophoresis (IFE), 276
Immunofluorescence
  immunoglobulin components, 120
  kidneys, 133
  in tissue, 131–132
Immunoglobulin light chain amyloidosis (AL), 12
Immunogold labeling, 124, 252, 253
Immunohistochemistry
  fibrillar protein, 87
  microglobulin amyloidosis, 77
  neurodegenerative diseases, 107
Immunomodulatory drugs (IMiDs), 382–383
Immunotactoid glomerulopathy
  extrarenal manifestations, 121–122
  pathogenesis, 122
Inflammatory bowel disease (IBD), 45–46
Infliximab, 400
Insulinoma, pancreas, 88–89
Interleukin-1 (IL-1) antagonists, 400
Islets of Langerhans, 84–86

J
Juvenile idiopathic arthritis (JIA), 33

K
Kidney amyloid, 305

L
Laser microdissection (LMD), 262
LECT2. See Leukocyte derived chemotaxin-2 (LECT2)
Lenalidomide, 383
Leukocyte derived chemotaxin-2 (LECT2), 64–65, 300
Lichen amyloidosis (LA), 82–84
Light and heavy chain deposition disease (LHCDD)
  diagnostic criteria/pitfalls, 136–137
  extrarenal manifestations, 133
  gastrointestinal, 135–136
  heart, 130–131, 134
  historical perspective, 132–133
  immunohistochemistry, 130–131
  kidneys, 133
  liver, 133–134
  lungs, 135
  muscle, 136
  nodular glomerulosclerosis, 130–132
  organ pathology, 138–139
  other organs, 136
  pancreas, 136
  peripheral and central nervous system involvement, 134
  skin, 136
Liver
  AL amyloid, 352, 357
  alcoholic steatohepatitis, 349
  alpha-1 antitrypsin globules, 350, 352
  clinical presentation, amyloid, 345–346
  Congo red stain, 349–350
  differential diagnosis, 348
  domino transplant, 353
  fibroscan, 346
  gallbladder, lamina propria, 354, 357
  globules, 350–351
  hepatomegaly, 345
  large rounded acellular hyalin material, 352, 356
  Lect 2 involvement, 352–355
  LHCDD, 133–134
  pancreatic islets, 358
  patterns of, amyloid, 347
  sinusoidal amyloid deposition, 347
  transthyretin, 352, 357
  trichrome stains, 348–349
Lobar hemorrhages, 106
Localized AL amyloids
  additional localized aggregates, 97–98
  amyloidoma, 83
  calcifying epithelial odontogenic (Pindborg) tumor, 91
  corneal amyloid, 95–96
  in endocrine organs and tumors
    amyloid stroma, 88
    cardiac amyloid, 86–87
    insulin injection, 88
    islets of Langerhans, 84–86
    parathyroid glands, 86–87
    pituitary gland, 87–88
    insulinoma of, pancreas, 88–89
    in joints, ligaments and tendons, 96–97
    medullary thyroid carcinoma, 88
    morphology, 82
    pituitary adenoma, 89
    in seminal vesicles, 95
  senile systemic amyloidosis
    aorta and other arteries, 93
    in atherosclerotic plaques and cardiac valves, 94–95
    medin (AMed) amyloid, 93–94
    in skin
      lichen amyloidosis (LA) and macular amyloidosis (MA), 82–84
      tumors, 91
Localized amyloidosis
  genitourinary tract, 312–313
  heart
    isolated atrial amyloidosis (IAA), 319–320
    senile aortic amyloid, 320
    valvular amyloidosis, 321
    laser therapy, 379
    renal involvement, 379
Index

Loss of chance, amyloidosis, 409–411
Lungs, 135
Lysozyme, 62–63, 299–300

M
Macular amyloidosis (MA), 89–90
Major histocompatibility complex (MHC), 38
Malpractice, 406
Medical advisory board, 413
Medin (AMed) amyloid, 93–94
Medullary thyroid carcinoma, 88
Melphalan-based therapies, 382
Membranoproliferative glomerulonephritis (MPGN), 143–145, 147, 149–152
Membranous nephropathy (MN), 144, 147–149
Mendelian autoinflammatory diseases. See Familial Mediterranean fever (FMF)
Monoclonal FLC. See Free light chain (FLC)
Monoclonal Ig deposits, 143–152
Monoclonal immunoglobulins, 275–276
Monogenic autoinflammatory diseases, 34
Muckle-Wells syndrome (MWS), 34, 41, 400
Muscle, 136

N
NALP3. See NLRP3 gene
Neonatal onset multisystem inflammatory disease (NOMID), 34, 35, 41–43, 400
Neoplasia associated CNS amyloidosis, 109
Nephelometry, 278
Nephropathy, 54, 116–119. See also Cryoglobulinemic nephropathy; Membranous nephropathy (MN)
NLRP3 gene, 18
NLRP3 inﬂammasome, 41–42, 45
Nodular glomerulosclerosis, 130–132
NOMID/CINCA, 42–43
Non-organized monoclonal deposits, 144
Non-Randall glomerulonephritis. See Glomerulonephritis (GN)

O
Oligomers, 10, 13, 16, 17, 84, 86
Online hemodiafiltration, 78
Organized deposits
entities, kidney and extrarenal manifestations, 114–115
glomerulonephritis (GN), 144
history, 113–114
problems, 115–116
Organ pathology, 138–139
Organ tropism, 12–13, 17

P
Pancreas, 136
Parathyroid glands, 86–87
Pathology
amyloid, 113–125
kidney, 155–159
neurodegenerative diseases, 106
Peripheral nerve amyloidosis
AL (primary), 367
biopsy sites, 362–363
clinical presentation, 362
familial amyloid polyneuropathy
apolipoprotein A-I, 370–371
gelsolin, 370
transhyretin, 369–370
focal, macroscopic aggregate, 366
historical pathology, 361
IgM macroglobulin deposition, 367–369
mass spectrophotometric evaluation, 366–367
pathogenesis and histopathology, 363–365
treatment of, 371
PGN MID. See Proliferative glomerulonephritis with monoclonal IgG deposits (PGN MID)
Pituitary adenoma, 89
Pituitary amyloid, 109
Pituitary gland, 87–88
Plasma cell dyscrasia (PCD)
CD138, 284–285
colorimetric in situ hybridization (CISH), 286
kappa and lambda light chain immunoglobulins, 285
pre-and posttreatment, 286–287
specimen analysis, 288
Polygenic and complex autoinflammatory disease, 44–45
Polypeptide hormone, 82, 86, 88
Primary (AL) amyloidosis
abnormal serum, 275–276
FLC (see Free light chain (FLC))
monitoring disease activity, 281
monoclonal free light chain, 276
monoclonal gammopathy distribution, 277
monoclonal protein and immunoglobulins, 275
multiple myeloma, 277
normal serum, 275–276
Proliferative glomerulonephritis with monoclonal IgG deposits (PGN MID), 144–146, 150, 151
Proteasome inhibitors, 383–384

R
Reactive amyloidosis. See AA amyloidosis
Rheumatic disease, 33, 399
Rilonacept, 400
Rosai-Dorfman disease. See Sinus histiocytosis with massive lymphadenopathy (SHML)

S
Sarcoidosis, 46
Selective β2m adsorption Lixelle column, 78
Seminal vesicles, 95
Senile systemic amyloidosis
  aorta and other arteries, 93
  in atherosclerotic plaques and cardiac valves, 94–95
  medin (AMed) amyloid, 93–94
Serum amyloid A (SAA), 32, 37–40, 46
Serum protein electrophoresis (SPEP), 275–276, 292
Sinus histiocytosis with massive lymphadenopathy (SHML), 46
siRNA, 395
Skin
  LHCDD, 136
  localized amyloids
    lichen amyloidosus (LA) and macular amyloidosis (MA), 82–84
  tumors, 91
Standard of care, amyloidosis, 408
Swissprot, 263
Systemic amyloidosis, 405
  AL amyloidosis, 381
  and CNS involvement, 109
  heart
    amyloid A protein, 323
    apolipoprotein A-I, 323–324
    β2-microglobulin, 323
    fibrinogen, 324
    immunoglobulin light chain, 321
    transthyretin, 321, 323
T
  Testis, 314, 315
  Thalidomide, 383
  Thioflavin T stain, 114, 116, 122, 130, 134–136, 187–189
  Tocilizumab, 400
Transthyretin (TTR). See also Familial amyloid polyneuropathy (FAP)
  amyloid fibril protein, 92
  associated familial amyloidosis, 323
  hereditary amyloidosis
    leptomeningeal and brain biopsy, 56–57
    liver transplantation, 295
    mass spectra, 296
    phenotypic correlations, 296–297
    plasma protein, 56–57
    prealbumin, 55
    senile amyloid deposition, 295
  SSA, 321, 323
Tumor necrosis factor receptor associated periodic syndrome (TRAPS), 39–41
Type 2 diabetes, 12, 82, 84, 86

U
  Ultrapure dialysate, 78
  Urinary bladder, 313
  Urine protein, 280